# Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Source: https://onco.cc/trials/nct07174427/  
OnCo record `nct07174427` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TBI-1301 in sarcomas, now recruiting.

## Summary

Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma is a phase 3 interventional study registered as NCT07174427, led by Takara Bio, and recruiting on the registry. Official title: Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma. Planned enrolment is 5 participants (estimated). The study started in 2026-01-05 and primary completion is expected in 2032-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07174427
- Phase: 3
- Setting: Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
- Sponsor: Takara Bio
- Enrolled: 5

## Sources

- ClinicalTrials.gov NCT07174427: https://clinicaltrials.gov/study/NCT07174427

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Synovial sarcoma](https://onco.cc/cancers/synovial-sarcoma/)
- drugs: [TBI-1301](https://onco.cc/drugs/tbi-1301/)
- companies: [Takara Bio](https://onco.cc/companies/takara-bio/)
- targets: [CTAG1B](https://onco.cc/targets/ctag1b/)

---
JSON: https://onco.cc/api/v1/entities/nct07174427.json